Randomized phase III study comparing etoposide and cisplatin (EP) with irinotecan and cisplatin (IP) following EP plus concurrent accelerated hyperfractionated thoracic radiotherapy (EP/AHTRT) for the treatment of limited-stage small-cell lung cancer (LD-SCLC): JCOG0202.
Kaoru Kubota
Honoraria - Daiichi Sankyo
Toyoaki Hida
No relevant relationships to disclose
Satoshi Ishikura
No relevant relationships to disclose
Junki Mizusawa
No relevant relationships to disclose
Makoto Nishio
Honoraria - Chugai Pharma
Masaaki Kawahara
No relevant relationships to disclose
Akira Yokoyama
No relevant relationships to disclose
Fumio Imamura
No relevant relationships to disclose
Koji Takeda
No relevant relationships to disclose
Shunichi Negoro
Honoraria - Yakult
Research Funding - Yakult
Masao Harada
No relevant relationships to disclose
Hiroaki Okamoto
Honoraria - Chugai Pharma; Janssen Pharmaceutical ; Kyowa Hakko Kirin; Lilly; Sanofi ; Taiho Pharmaceutical
Nobuyuki Yamamoto
No relevant relationships to disclose
Tetsu Shinkai
No relevant relationships to disclose
Hiroshi Sakai
Honoraria - Chugai Pharma; Lilly; Sanofi ; Taiho Pharmaceutical
Kaoru Matsui
No relevant relationships to disclose
Kazuhiko Nakagawa
No relevant relationships to disclose
Taro Shibata
No relevant relationships to disclose
Nagahiro Saijo
No relevant relationships to disclose
Tomohide Tamura
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Taiho Pharmaceutical; Yakult